Clinical aspects of the use of Anti-CGRP monoclonal antibodies in the prevention of migraine: a description of a clinical case

V.V. Osipova, Yu.V. Vorobiev, A.R. Artemenko, K.V. Skorobogatikh

1) University Headache Clinic, Moscow, Russia; 2) Z.P. Solovyev Research and Clinical Center for Neuropsychiatry of the Moscow Healthcare Department, Moscow, Russia; 3) Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 4) Center for Interdisciplinary Dentistry and Neurology, Moscow, Russia

The article presents a brief description and advantages of a new targeted migraine therapy from the class of monoclonal antibodies to migraine pain mediator – calcitonin-gene-related peptide or its receptor (Anti-CGRP(r) mAb). Special attention is paid to the efficacy and tolerability criteria of the Anti-CGRP(r) mAb class. On the example of a clinical case of frequent episodic migraine in a young woman, the problems of choosing preventive therapy, taking into account comorbidity and individual preferences of the patient, are discussed. The presented case illustrates the difficulties that may arise during long-term management of the patient and the possibility of increasing the effectiveness of preventive treatment of migraine when switching from one Anti-CGRP mAb(r) to another drug of this class.

Keywords

About the Authors

Corresponding author: Vera V. Osipova, Dr. Sci. (Med.), University Headache Clinic (Moscow), Z.P. Solovyev Research and Clinical Center for Neuropsychiatry of the Moscow Healthcare Department, Moscow, Russia; osipova_v@mail.ru

Similar Articles